ArticleResearch in autism spectrum disorders2012
TARGETED TREATMENTS IN AUTISM AND FRAGILE X SYNDROME.
Article in Research in autism spectrum disorders, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 43 citations in OpenAlex.
- Individual differences in social homeostasis.Frontiers in behavioral neuroscience · 2023Review
- Asperger Syndrome (AS): A Review Article.Cureus · 2022Review
- Enriched Environments as a Potential Treatment for Developmental Disorders: A Critical Assessment.Frontiers in psychology · 2019Review
- Metabotropic glutamate receptor 5 tracer [Cerebellum & ataxias · 2018Article
- Fragile X Syndrome FMRP Co-localizes with Regulatory Targets PSD-95, GABA Receptors, CaMKIIα, and mGluR5 at Fiber Cell Membranes in the Eye Lens.Neurochemical research · 2015Article
- Endocannabinoid Signaling in Autism.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Review
- Diametrical diseases reflect evolutionary-genetic tradeoffs: Evidence from psychiatry, neurology, rheumatology, oncology and immunology.Evolution, medicine, and public health · 2015Review
- GABA receptor subunit distribution and FMRP-mGluR5 signaling abnormalities in the cerebellum of subjects with schizophrenia, mood disorders, and autism.Schizophrenia research · 2015Review
- Autism Symptomatology in Boys with Fragile X Syndrome: A Cross Sectional Developmental Trajectories Comparison with Nonsyndromic Autism Spectrum Disorder.Journal of autism and developmental disorders · 2015Article
- KCC2 expression supersedes NKCC1 in mature fiber cells in mouse and rabbit lenses.Molecular vision · 2015Article
- Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders.Brain research · 2014Review
- The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment.Journal of neural transmission (Vienna, Austria : 1996) · 2014Review
- Downregulation of GABAA receptor protein subunits α6, β2, δ, ε, γ2, θ, and ρ2 in superior frontal cortex of subjects with autism.Journal of autism and developmental disorders · 2014Article
- Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder.Research in developmental disabilities · 2014Article
- Newborn screening for fragile X syndrome.JAMA neurology · 2014Review
- The fragile X syndrome-autism comorbidity: what do we really know?Frontiers in genetics · 2014Article
- The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome.Current neuropharmacology · 2014Article
- Increased glutamate concentration in the auditory cortex of persons with autism and first-degree relatives: a (1)H-MRS study.Autism research : official journal of the International Society for Autism Research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Autism is a neurodevelopmental disorder consisting of a constellation of symptoms that sometimes occur as part of a complex disorder characterized by impairments in social interaction, communication and behavioral domains. It is a highly disabling disorder and there is a need for treatment targeting the core symptoms. Although autism is accepted as highly heritable, there is no genetic cure at this time. Autism is shown to be linked to several genes and is a feature of some complex genetic disorders, including fragile X syndrome (FXS), fragile X premutation involvement, tuberous sclerosis and Rett syndrome. The term autism spectrum disorders (ASDs) covers autism, Asperger syndrome and pervasive developmental disorders (PDD-NOS) and the etiologies are heterogeneous. In recent years, targeted treatments have been developed for several disorders that have a known specific genetic cause leading to autism. Since there are significant molecular and neurobiological overlaps among disorders, targeted treatments developed for a specific disorder may be helpful in ASD of unknown etiology. Examples of this are two drug classes developed to treat FXS, Arbaclofen, a GABA(B) agonist, and mGluR5 antagonists, and both may be helpful in autism without FXS. The mGluR5 antagonists are also likely to have a benefit in the aging problems of fragile X premutation carriers, the fragile X -associated tremor ataxia syndrome (FXTAS) and the Parkinsonism that can occur in aging patients with fragile X syndrome. Targeted treatments in FXS which has a well known genetic etiology may lead to new targeted treatments in autism.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.